ClinicalTrials.gg
RecruitingNCT07853898Updated Oct 2, 2026

Effects of Pistachios on Postprandial Metabolic Responses in Adults With Overweight or Obesity

An interventional study of Pistachio Co-consumption and Refined-Carbohydrate Control Co-consumption in Obesity / Overweight, sponsored by St. Louis University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by St. Louis University · Not applicable, Interventional, and Basic science

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

This randomized controlled crossover study will examine the acute effects of pistachio consumption on postprandial metabolic responses in adults with overweight or obesity. Participants will complete two experimental conditions in randomized order. In one condition, participants will consume 30 g of pistachios with a standardized meal, and in the other condition they will receive an isocaloric refined-carbohydrate control condition with the standardized meal.

The study will evaluate postprandial insulin and glucose responses over approximately 3 hours after meal consumption. Additional outcomes will include continuous glucose monitoring measures, blood lipid responses, appetite and satiety ratings, and exploratory measures related to insulin sensitivity and gastrointestinal hormone responses. The study is designed to determine whether pistachio consumption alters acute metabolic responses compared with an isocaloric refined-carbohydrate control in adults with overweight or obesity.

Read the detailed description

This study is a randomized, controlled, crossover feeding trial designed to investigate the acute effects of pistachio consumption on postprandial metabolic responses in adults with overweight or obesity. Each participant will complete both experimental conditions in randomized order, thereby serving as their own control. Experimental visits will be separated by a washout period.

After an overnight fast, participants will receive either 30 g of pistachios or an isocaloric refined-carbohydrate control with a standardized meal. Serial blood samples will be collected during the postprandial period to assess insulin and glucose responses. The primary metabolic outcome will focus on the postprandial insulin response over the 0- to 180-minute period.

Additional outcomes will characterize postprandial glucose responses, including measures obtained using continuous glucose monitoring, as well as appetite and satiety ratings and blood lipid responses. Exploratory analyses may include indices of insulin sensitivity and resistance and gastrointestinal hormones involved in metabolic regulation. The crossover design will allow direct within-participant comparison of the pistachio and control conditions.

02

Conditions studied

  • Obesity / Overweight

Keywords

  • Pistachios
  • Postprandial glucose
  • Postprandial insulin
  • Metabolic response
  • Insulin sensitivity
  • Continuous glucose monitoring
  • Appetite
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 28 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

St. Louis University is the lead sponsor of 156 studies on the registry; 17 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-35 years, male or female, and able to provide .
  • ≥25.0 kg/m². Waist circumference and BIA-derived body composition will also be assessed during screening and considered with BMI to help confirm that elevated BMI reflects excess adiposity rather than primarily high muscularity.
  • Weight stable, defined as no intentional weight loss or body weight change >3 kg during the previous 3 months.
  • Generally healthy and not currently taking medications known to substantially affect glucose metabolism, insulin secretion, insulin sensitivity, appetite, or body weight. Stable thyroid hormone replacement for a well-controlled thyroid condition is not automatically exclusionary.
  • Able to complete a 10-12-hour overnight fast and refrain from vigorous exercise and alcohol for 24 hours before each test meal visit.
  • Able and willing to consume pistachios, the refined-carbohydrate control food, and the standardized breakfast meal.

Exclusion criteria

Exclusion Criteria:

  • Known diagnosis of type 1 or type 2 diabetes. Individuals with known prediabetes will not be excluded.
  • cardiovascular disease, including prior myocardial infarction or stroke, uncontrolled hypertension, clinically significant arrhythmia, or another cardiovascular condition that could make participation unsafe or meaningfully affect study outcomes.
  • Chronic kidney disease or another major medical condition that could make participation unsafe or meaningfully affect metabolic outcomes.
  • Current participation in a weight-loss program, use of weight-loss medications, or history of bariatric surgery within the past year.
  • Known allergy or intolerance to pistachios, tree nuts, peanuts/peanut butter, wheat/gluten, orange juice/citrus, or any other study-meal ingredient.
  • Celiac disease, Crohn's disease, ulcerative colitis, or another clinically significant gastrointestinal or malabsorption condition that could affect digestion, nutrient absorption, or metabolic responses.
  • Current ketogenic, very-low-carbohydrate, or medically prescribed diet that could meaningfully interfere with the standardized feeding protocol or metabolic outcomes.
  • Participation in another clinical research trial within the past 3 months that could affect participant safety or study outcomes.
  • Recent significant illness, infection, or surgery within the past 4 weeks that could affect participant safety or study outcomes.
  • Current or prior clinically significant eating disorder that, in the investigator's judgment, could make participation unsafe or interfere with the feeding protocol.
  • Current smoking, frequent nicotine use, or excessive alcohol use.
  • Pregnancy, planned pregnancy during the study period, or lactation.
  • Any condition or medication that, in the investigator's judgment, would make participation unsafe or interfere with outcome measures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Pistachio Then Control Sequence

    Participants randomized to this sequence will first complete the pistachio condition, in which 30 g of shelled pistachios are consumed with the standardized high-glycemic breakfast meal. After a 3-7 day washout period, participants will complete the refined-carbohydrate control condition, in which an isocaloric refined-carbohydrate control food is consumed with the same standardized breakfast meal.

    Other: Pistachio Co-consumption · Other: Refined-Carbohydrate Control Co-consumption

  • Experimental
    Control Then Pistachio Sequence

    Participants randomized to this sequence will first complete the refined-carbohydrate control condition, in which an isocaloric refined-carbohydrate control food is consumed with the standardized high-glycemic breakfast meal. After a 3-7 day washout period, participants will complete the pistachio condition, in which 30 g of shelled pistachios are consumed with the same standardized breakfast meal.

    Other: Pistachio Co-consumption · Other: Refined-Carbohydrate Control Co-consumption

Interventions

  • OtherPistachio Co-consumption

    Participants will consume 30 g of shelled, lightly salted pistachios together with a standardized high-glycemic breakfast meal. The pistachios and standardized breakfast meal will be consumed within a fixed 10-minute meal period.

  • OtherRefined-Carbohydrate Control Co-consumption

    Participants will consume an isocaloric refined-carbohydrate control food together with the same standardized high-glycemic breakfast meal. The control food will be matched to the pistachio condition for energy content as closely as possible while providing minimal fiber, protein, unsaturated fat, and bioactive compounds.

06

What researchers measure

Primary outcomes

  1. Postprandial Insulin Incremental Area Under the Curve (iAUC)

    Postprandial plasma insulin will be measured at 0, 30, 60, 90, 120, 150, and 180 minutes after meal consumption. Insulin incremental area under the curve (iAUC) from 0 to 180 minutes will be calculated using the trapezoidal rule with baseline subtraction. Insulin iAUC will be compared between the pistachio and refined-carbohydrate control conditions.

    Time frame: 0-180 minutes after meal consumption

Secondary outcomes

  1. Postprandial Plasma Glucose Incremental Area Under the Curve (iAUC)

    Plasma glucose concentrations will be measured at 0, 30, 60, 90, 120, 150, and 180 minutes after meal consumption. Glucose iAUC from 0 to 180 minutes will be calculated using the trapezoidal rule with baseline subtraction and compared between conditions.

    Time frame: 0-180 minutes after meal consumption

  2. Continuous Glucose Monitoring Time in Range

    Percentage of CGM glucose readings within the predefined range of 70-180 mg/dL during the postprandial laboratory monitoring period will be calculated and compared between the pistachio and refined-carbohydrate control conditions.

    Time frame: 0-180 minutes after meal consumption

  3. Continuous Glucose Monitoring Mean Glucose

    Mean interstitial glucose concentration measured by continuous glucose monitoring during the postprandial laboratory monitoring period will be calculated and compared between conditions.

    Time frame: 0-180 minutes after meal consumption

  4. Continuous Glucose Monitoring Glycemic Variability

    Glycemic variability will be assessed using the coefficient of variation (CV) of CGM-derived interstitial glucose concentrations during the postprandial monitoring period and compared between conditions.

    Time frame: 0-180 minutes after meal consumption

  5. Continuous Glucose Monitoring Peak Glucose

    The highest interstitial glucose concentration recorded by continuous glucose monitoring during the postprandial monitoring period will be determined and compared between conditions.

    Time frame: 0-180 minutes after meal consumption

  6. Continuous Glucose Monitoring Time to Peak Glucose

    Time from meal consumption to the highest CGM-derived interstitial glucose concentration during the postprandial monitoring period will be determined and compared between conditions.

    Time frame: 0-180 minutes after meal consumption

  7. Postprandial Hunger Rating

    Self-reported hunger will be assessed using a 100-mm visual analog scale (VAS) at baseline and 30, 60, 120, and 180 minutes after meal consumption and compared between conditions.

    Time frame: Baseline and 30, 60, 120, and 180 minutes after meal consumption

  8. Postprandial Fullness Rating

    Self-reported fullness will be assessed using a 100-mm visual analog scale (VAS) at baseline and 30, 60, 120, and 180 minutes after meal consumption and compared between conditions.

    Time frame: Baseline and 30, 60, 120, and 180 minutes after meal consumption

  9. Postprandial Satisfaction Rating

    Self-reported satisfaction will be assessed using a 100-mm visual analog scale (VAS) at baseline and 30, 60, 120, and 180 minutes after meal consumption and compared between conditions.

    Time frame: Baseline and 30, 60, 120, and 180 minutes after meal consumption

  10. Postprandial Desire to Eat Rating

    Self-reported desire to eat will be assessed using a 100-mm visual analog scale (VAS) at baseline and 30, 60, 120, and 180 minutes after meal consumption and compared between conditions.

    Time frame: Baseline and 30, 60, 120, and 180 minutes after meal consumption

Other outcomes

  1. Postprandial Plasma Triglycerides

    Plasma triglyceride concentrations will be assessed before and after the test meal to evaluate the acute postprandial lipid response and compared between the pistachio and refined-carbohydrate control conditions.

    Time frame: Baseline and 180 minutes after meal consumption

  2. Postprandial Glucagon-Like Peptide-1 (GLP-1) Concentrations

    GLP-1 concentrations will be assessed from stored plasma samples to explore the acute incretin response to the pistachio and refined-carbohydrate control conditions, if funding and sample availability permit.

    Time frame: During the 0-180-minute postprandial period

  3. Postprandial Glucose-Dependent Insulinotropic Polypeptide (GIP) Concentrations

    GIP concentrations will be assessed from stored plasma samples to explore the acute incretin response to the pistachio and refined-carbohydrate control conditions, if funding and sample availability permit.

    Time frame: During the 0-180-minute postprandial period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not currently planned to be shared with researchers outside the study team. Study results will be reported in aggregate or de-identified form in accordance with applicable institutional, ethical, and privacy requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 9 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 2, 2026
StartEst.
Oct 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853898
Responsible party
Hossein Rafiei (Assistant Professor, St. Louis University) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Hossein Rafiei, PhD, RD
Contact
hossein.rafiei@health.slu.edu
314-977-8675
Hossein Rafiei, PhD, RD
principal investigator · St. Louis University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion